Berlin-based VC naturalX Health Ventures has announced a €100 million fund to “fuel the future of consumer health in Europe” and to support “proactive healthcare, filling a market gap as consumers take control of their own health journey.”
naturalX was founded by Marvin Amberg, a German serial entrepreneur with experience launching consumer and health startups, in cooperation with Schwabe Group, the plant-based pharmaceuticals firm.
naturalX Health Ventures said it will be the first specialized fund “focused exclusively on the intersection of consumer and health in the European market.”
The fund will focus primarily on Series-A investments “while remaining flexible to participate in late Seed and Series-B rounds.”
Typical first investments range from €3 million to €5 million, with up to €10 million available per company.
“naturalX can act as either lead investor or co-investor, targeting consumer health startups across Europe with selected investments in North America,” said naturalX Health Ventures.
The fund defines consumer health as “the intersection of wellness and medicine, where science-backed products and services put the consumer in focus.”
naturalX Health Ventures said: “During its 18-month ramp-up phase, naturalX has already made several investments, including mybacs, Flow Neuroscience, Kyan Health, and Meela, while also investing in healthcare-focused VC funds to build a strong ecosystem around their thesis.”
Amberg said: “I am very excited to double down on our thesis with the official launch of naturalX. The consumer health space has been overlooked by investors.
“We see an inflection point in Europe now, as consumers are finally taking more charge of their own health. Startups in the space need a partner with a shared vision …
“We analysed the U.S. health market and in many successful startups, the consumer is already at the centre. Our thesis is that this is just the beginning, and the European market will develop in a similar pattern.
“While we start to see some examples of consumer-focused healthcare companies in Europe reaching meaningful scale and significant funding, such as Oura or Neko Health, we think this market deserves more attention.”